Stock Research for ACHN

ACHN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACHN Stock Chart & Research Data

The ACHN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACHN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACHN Due diligence Resources & Stock Charts

The ACHN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACHN Detailed Price Forecast - CNN Money CNN View ACHN Detailed Summary - Google Finance
Yahoo View ACHN Detailed Summary - Yahoo! Finance Zacks View ACHN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACHN Trends & Analysis - Trade-Ideas Barrons View ACHN Major Holders - Barrons
NASDAQ View ACHN Call Transcripts - NASDAQ Seeking View ACHN Breaking News & Analysis - Seeking Alpha
Spotlight View ACHN Annual Report - CompanySpotlight.com OTC Report View ACHN OTC Short Report - OTCShortReport.com
TradeKing View ACHN Fundamentals - TradeKing Charts View ACHN SEC Filings - Bar Chart
WSJ View Historical Prices for ACHN - The WSJ Morningstar View Performance/Total Return for ACHN - Morningstar
MarketWatch View the Analyst Estimates for ACHN - MarketWatch CNBC View the Earnings History for ACHN - CNBC
StockMarketWatch View the ACHN Earnings - StockMarketWatch MacroAxis View ACHN Buy or Sell Recommendations - MacroAxis
Bullish View the ACHN Bullish Patterns - American Bulls Short Pains View ACHN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACHN Stock Mentions - StockTwits PennyStocks View ACHN Stock Mentions - PennyStockTweets
Twitter View ACHN Stock Mentions - Twitter Invest Hub View ACHN Investment Forum News - Investor Hub
Yahoo View ACHN Stock Mentions - Yahoo! Message Board Seeking Alpha View ACHN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACHN - SECform4.com Insider Cow View Insider Transactions for ACHN - Insider Cow
CNBC View ACHN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACHN - OTC Markets
Yahoo View Insider Transactions for ACHN - Yahoo! Finance NASDAQ View Institutional Holdings for ACHN - NASDAQ


Stock Charts

FinViz View ACHN Stock Insight & Charts - FinViz.com StockCharts View ACHN Investment Charts - StockCharts.com
BarChart View ACHN Stock Overview & Charts - BarChart Trading View View ACHN User Generated Charts - Trading View




Latest Financial News for ACHN


Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report?
Posted on Saturday April 06, 2019

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.


Achillion Meets Enrollment Target in Kidney Disease Studies
Posted on Thursday April 04, 2019

Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.


Why Achillion Pharmaceuticals Stock Is Jumping Today
Posted on Wednesday April 03, 2019

Reaching a key clinical study milestone provided a nice boost to the biotech stock.


Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy
Posted on Wednesday April 03, 2019

Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that it achieved threshold enrollment in the Phase 2 trials of ACH-4471 for patients with C3 glomerulopathy (C3G), a devastating disease affecting the kidney for which there is no approved therapy. ACH-4471 will be evaluated in the six-month blinded, placebo-controlled trial (11 patients) and the 12-month open-label trial (12 patients). “Enrolling our ACH-4471 Phase 2 trials is an important milestone for Achillion, and we would like to thank all of the patients, families, investigators and participating clinical trial sites for their outstanding contributions,” said Joe Truitt, President and Chief Executive Officer at Achillion.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.